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MicroRNAs (miRNAs) are small non-coding RNAs
that inhibit the expression of target genes by pro-
moting mRNA degradation or inhibiting mRNA
translation. In plants and invertebrates, miRNAs
are involved in the innate response to invading
viruses, but it was not known whether they per-
formed similar functions in mammals. Several
recent publications underscore the antiviral effects
of miRNAs against important human pathogens.
Other studies highlight the complex interplay
between viruses and the cellular RNA interference
(RNAi) machinery, with viruses that encode their
own miRNAs and viruses that actually employ
cellular miRNAs as cofactors for replication. These
virus–cell interactions are illustrated in the Figure.
Although many obstacles remain, miRNA mim-
ics or miRNA inhibitors could hold promise for
the design of a new generation of antiviral drugs.
Hepatitis C Virus
Approximately 2% of the human population
worldwide are infected with hepatitis C virus
(HCV), and about 50–80% of those people de-
velop persistent infections and are at great risk for
developing liver cancer. The only approved therapy
for HCV is alpha-interferon. Reporting in Nature,
Pedersen and colleagues show that a set of cellular
miRNAs are induced by the interferon system.1
Of these miRNAs, eight have a nearly perfect match
in the HCV RNA genome and five were shown to
actively inhibit HCV replication. A mixture of these
five inhibitors (synthetic miRNA mimics) was
able to reduce HCV mRNA levels by 80%.
Thus, miRNAs contribute to the antiviral 
effects of interferon, but this is not the complete
story at the miRNA–HCV interface. A fascinating
previous study by Jopling and colleagues demon-
strated that HCV uses one particular miRNA
(miR-122) as a positive cofactor in its replication
cycle.2 This miR-122 is abundantly expressed in
liver cells in which HCV replicates. Interestingly,
the Pedersen et al study showed that this miR-
122 cofactor is in fact specifically downregulated
by interferon. These results highlight the complex
interplay between HCV and the cellular RNAi
machinery.
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Figure. Examples of miRNA-mediated effects on the virus–host cell interaction. The examples shown are discussed in the
text. The +/− signs mark the impact on the virus, and it is assumed that the establishment of HIV-1 latency is beneficial
for the virus.
NEWS AND PERSPECTIVES
Human Immunodeficiency Virus
There is rapidly mounting evidence of an intricate
interaction between the human immunodeficiency
virus type 1 (HIV-1) and the RNAi machinery.
Firstly, HIV-1 was shown to encode an RNAi sup-
pressor protein in the form of the small Tat pro-
tein.3,4 Secondly, the RNAi silencing machinery
was shown to be involved in the control of HIV-1
replication because lowering the cellular levels 
of the Dicer and Drosha components of this 
machinery led to enhanced virus replication.5
Whereas these results could be interpreted in terms
of cellular protection against HIV-1 and viral
countermeasures, it again does not seem to be
the complete story.
The recent study by Huang et al indicates that
HIV-1 uses miRNA-mediated downregulation of
viral gene expression to its own advantage by 
allowing a state of viral latency.6 HIV-1 latency
means that the provirus is stably integrated into
the host genome, but is not producing any viral
transcripts and proteins. This latency is thought
to help HIV-1 evade immune responses and 
the action of antiretroviral drugs, and it is a
major hurdle that must be overcome by attempts
to eradicate the virus in an infected individual.
Huang and colleagues showed that a set of
miRNAs is enriched in resting T cells that harbor
these latent proviruses, and five of these miRNAs
have predicted binding sites in the HIV-1 genome.
Inhibition of these miRNAs in resting T cells from
patients indeed boosted viral gene expression.
Virus-encoded miRNAs
There is a growing list of DNA viruses that encode
their own miRNAs, including the herpes viruses.
Several mechanistic scenarios have been proposed.
Firstly, certain viral miRNAs downregulate the
expression of viral mRNAs that are expressed from
the opposite DNA strand. Secondly, viral miRNAs
may inhibit the expression of cellular mRNAs. 
A third mechanism was recently proposed in a
study by Gotwein and colleagues that focused on
a particular miRNA encoded by the herpes virus
associated with Kaposi’s sarcoma.7 This viral
miRNA has been found to mimic the ubiquitous
cellular miR-155, and may have evolved to exploit
an existing gene regulatory pathway in B cells.
miR-155 is induced on B cell activation and over-
expressed in many human B cell lymphomas.
Many candidate mRNA targets have been identi-
fied, but it is currently unclear manipulation of
which cellular pathways provides a replication
advantage to the virus.
Therapeutic Consequences
These newly discovered virus–cell interactions
with respect to the RNAi mechanism may have
implications for therapeutic attempts to control
virus replication by induced antiviral RNAi ap-
proaches. For instance, the presence of a viral RNAi
suppressor protein may seem bad news for such
therapeutic interventions. However, very promis-
ing results have been reported against both HCV
and HIV-1 in in vitro gene therapy settings.8,9 In
fact, the new insights at the virus–RNAi interface
may present new therapeutic options.10 One could
use the miRNAs that specifically suppress patho-
genic viruses as templates to design miRNA mim-
ics as a new class of antivirals. Alternatively, one
could try to block the cellular miRNAs that act as
viral cofactors, or the virally-encoded miRNAs,
by antisense inhibitors. Of course, more detailed
mechanistic insight is needed to produce safe
therapeutics that avoid unwanted and potentially
dangerous side effects.
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